Cargando…
Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
Vitamin K antagonist such as warfarin reduces the risk of stroke in atrial fibrillation (AF) patients. Since warfarin has a narrow therapeutic index, its administration needs to be regularly monitored to avoid any adverse clinical outcomes such as stroke and bleeding. The quality of anticoagulation...
Autores principales: | Zawawi, Nur Azyyati, Abdul Halim Zaki, Izzati, Ming, Long Chiau, Goh, Hui Poh, Zulkifly, Hanis Hanum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635010/ https://www.ncbi.nlm.nih.gov/pubmed/34869639 http://dx.doi.org/10.3389/fcvm.2021.736143 |
Ejemplares similares
-
Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022) -
Clinical characteristics and risk factors for mortality in patients with COVID-19: A retrospective nationwide study in Malaysia
por: Ismail, Siti NA, et al.
Publicado: (2022) -
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review
por: Suhaimi, Siti Nur Atikah Aishah, et al.
Publicado: (2023) -
A Review of the Prevalence of Thromboembolic Complications among Pregnant Women Infected with COVID-19
por: Mohd Ariff, Nurul Syafiqah, et al.
Publicado: (2022) -
Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists
por: Zulkifly, Hanis H., et al.
Publicado: (2023)